59 studies found for:    HIV AND "treatment naive" | Open Studies | HIV
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df
2 Recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide;   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
3 Recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide;   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
4 Unknown  The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects
Condition: HIV Infections
Interventions: Drug: nevirapine;   Drug: atazanavir/ritonavir
5 Recruiting Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: ritonavir + atazanavir + emtricitabine/tenofovir df
6 Recruiting Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
Conditions: Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Intervention: Drug: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF)
7 Unknown  Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: Raltegravir;   Drug: Atazanavir/Ritonavir
8 Recruiting Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Cobicistat;   Drug: Darunavir
9 Recruiting Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa
Conditions: HIV;   Impaired Cognition
Interventions: Drug: standard care;   Drug: novel treatment
10 Recruiting A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone Maintenance
Conditions: HIV;   HIV Infections
Intervention: Drug: Raltegravir
11 Unknown  Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients
Conditions: Acquired Immune Deficiency Syndrome;   HIV Infections
Interventions: Drug: first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);   Drug: second line ARV therapy (3TC+TDF+LPV/RTV)
12 Unknown  Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment
Condition: HIV Infections
Interventions: Drug: lamivudine, abacavir , ritonavir, atazanavir;   Drug: emtricitabine, tenofovir, ritonavir, atazanavir
13 Not yet recruiting Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection
Condition: HIV
Interventions: Drug: atripla;   Drug: darunavir ritonavir raltegravir
14 Unknown  Controlling Acute or Early HIV Infection With Antiretroviral Drugs, With or Without a Candidate Vaccine
Condition: HIV Infections
Interventions: Biological: HIV-1 immunogen;   Biological: HIV-1 Immunogen
15 Recruiting Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis
Conditions: HIV Infection;   Osteopenia;   Osteoporosis
Intervention:
16 Recruiting A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects
Conditions: Chronic Hepatitis C;   Human Immunodeficiency Virus
Intervention: Drug: sofosbuvir + Ribavirin (RBV)
17 Recruiting A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)
Condition: HIV Infections
Interventions: Drug: MK-1439;   Drug: Efavirenz;   Drug: TRUVADA®
18 Recruiting Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine
Conditions: Acute HIV Infection;   HIV Infections
Intervention: Drug: Darunavir/Ritonavir and Etravirine
19 Recruiting Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients
Condition: HIV
Intervention: Drug: MVC/RAL/FTC/TDF followed by Maraviroc/Raltegravir
20 Recruiting Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Conditions: HIV;   HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years